Table 3.
Number of patients with COPD-related health care utilization in the 12 months following therapy initiation: comparison of TIO to FSC and IPR to FSC using two analysis methods
| COPD-related utilization category | Multivariable regression analysis13 patients with any encounter: n (%) | Propensity score-matched analysis, patients with any encounter: n (%) | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| FSC n = 12,595 |
TIO n = 9126 |
P valuea | FSC n = 8135 |
TIO n = 8135 |
P valuea | |
| Outpatient visit | 3615 (28.7) | 3661 (40.1) | <0.001 | 2567 (31.6) | 3147 (38.7) | <0.001 |
| Outpatient visit with antibiotic | 490 (3.9) | 478 (5.2) | <0.001 | 355 (4.4) | 402 (4.9) | 0.08 |
| Outpatient visit with oral corticosteroid | 261 (2.1) | 262 (2.9) | 0.001 | 178 (2.2) | 224 (2.8) | 0.02 |
| ED visit | 450 (3.6) | 427 (4.7) | <0.001 | 277 (3.4) | 366 (4.5) | <0.001 |
| Hospitalization | 446 (3.5) | 413 (4.5) | <0.001 | 314 (3.9) | 343 (4.2) | 0.25 |
| Hospitalization/ED visit | 819 (6.5) | 764 (8.4) | <0.001 | 544 (6.7) | 647 (8.0) | 0.002 |
|
FSC n = 12,595 |
IPR n = 10,617 |
P valuea |
FSC n = 8514 |
IPR n = 8514 |
P valuea | |
|
|
||||||
| Outpatient visit | 3615 (28.7) | 3788 (35.7) | <0.001 | 2501 (29.4) | 2940 (34.5) | <0.001 |
| Outpatient visit with antibiotic | 490 (3.9) | 617 (5.8) | <0.001 | 358 (4.2) | 454 (5.3) | <0.001 |
| Outpatient visit with oral corticosteroid | 261 (2.1) | 354 (3.3) | <0.001 | 189 (2.2) | 269 (3.2) | <0.001 |
| ED visit | 450 (3.6) | 778 (7.3) | <0.001 | 322 (3.8) | 566 (6.6) | <0.001 |
| Hospitalization | 446 (3.5) | 651 (6.1) | <0.001 | 328 (3.9) | 475 (5.6) | <0.001 |
| Hospitalization/ED visit | 819 (6.5) | 1284 (12.1) | <0.001 | 594 (7.0) | 945 (11.1) | <0.001 |
Notes:
a
Calculated using chi-square test.
Abbreviations: COPD, chronic obstructive pulmonary disease; ED, emergency department; FSC, fluticasone propionate/salmeterol combination; IPR, ipratropium; TIO, tiotropium.